Comprehensive neuropsychological assessments, FDG and tau PET scans, and plasma NfL and GFAP levels are useful and more sensitive than evaluating symptoms and visual reading of brain atrophy on MRI in the early identification of genetic svPPA patients with the MAPT mutation. This evidence concerns the gene MAPT and Brain atrophy.